Continuing Medical Education (CME) Article from Psychiatric Times: Current Treatments for Cannabis Use Disorder
This 1 CME credit article evaluates evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder.
Our sister publication, Psychiatric Times, is currently offering a continuing medical education (CME) article for 1 credit. According to their website, the goal of this activity is to evaluate evidence-based behavioral treatments, medications, and management strategies for cannabis use disorder. This accredited continuing education (CE) activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals seeking to improve the care of patients with mental health disorders.
Premiere Date: December 20, 2022
Expiration Date: June 20, 2024
Click here to read the CME article from Psychiatric Times: https://www.psychiatrictimes.com/view/current-treatments-for-cannabis-use-disorder
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
